Cell and Gene Therapy Is Not Dead —It Is Being Rebuilt From the Ground Up

6 days ago
9 min read

The first wave of cell and gene therapy is maturing. The second wave — cheaper, broader, and targeting markets ten times larger — is where investors should be looking.

Prepared by Richstorm.co

Key Takeaways

Cell and gene therapy generated over $14 billion in global revenue in 2024 — and the five leading drugs are growing, not shrinking.
The 'CGT is dead' narrative confuses a broken pricing model with failed science. The biology works. The business model does not — yet.
In a single seven-month window in 2025, major pharmaceutical companies spent over $6.6 billion acquiring next-generation cell therapy companies at pre-commercial stage.
The next wave of innovation targets three areas: delivering therapy directly inside the body (eliminating the manufacturing problem), treating autoimmune diseases (a $150B+ market), and eventually cracking solid tumors.
China has become a genuine source of scientific innovation in this field — not just manufacturing — with multiple Chinese biotechs attracting billion-dollar Western partnerships.

The 'Dead' Narrative Gets the Diagnosis Wrong

If you follow healthcare news, you have probably heard that cell and gene therapy is in trouble. Drugs launched at million-dollar price tags with nobody buying them. A gene therapy for hemophilia that Pfizer approved and then pulled from the market in 2025 because not a single patient received it after approval. A pioneering company, bluebird bio, that split itself in two under the weight of manufacturing failures and financial losses.

That narrative is not wrong — as a description of the first generation of these therapies. But it confuses a broken business model with failed science. And that distinction matters enormously for investors.

Think of it this way. The first automobiles were loud, unreliable, expensive, and required a person with a hand crank to start them. By 1910, serious observers were writing that the automobile experiment had largely failed. They were describing real problems with real cars. What they missed was that those problems were engineering problems — solvable — not fundamental flaws in the idea of a combustion engine.

Cell and gene therapy is at a similar inflection point. The science is not broken. The delivery system, the pricing, and the manufacturing — those are broken. And an entirely new generation of companies is being built to fix exactly those things, with billions of dollars of pharmaceutical industry conviction behind them.

What Cell and Gene Therapy Actually Is — Without the Jargon

Your body fights disease using immune cells called T-cells — think of them as your body's security forces. In cancer, those security forces fail to recognize the threat because cancer cells disguise themselves as normal tissue.

Cell therapy is the process of taking a patient's own T-cells out of their blood, sending them to a laboratory, retraining them to recognize and attack specific cancer cells, multiplying them into hundreds of millions of copies, and putting them back into the patient's body. Instead of carpet-bombing the whole body with chemotherapy — which is what conventional cancer treatment does, killing healthy cells along with cancerous ones — you are sending in a specifically trained unit that knows exactly who the enemy is.

Gene therapy goes one step further: instead of modifying cells outside the body and returning them, it delivers genetic instructions directly inside the patient to reprogram their own cells in place. No extraction. No laboratory manufacturing. The drug finds the right cells inside the body and teaches them what to do.

This distinction — between the current 'take it out, fix it, put it back' approach and the next-generation 'fix it inside' approach — is the central technology shift driving billions of dollars of investment right now, and we will return to it.

The Commercial Reality: Five Drugs, Real Revenue, Real Growth

Before discussing what comes next, it is worth being clear about what already exists. Five cell therapy drugs are commercially approved and generating meaningful revenue — and despite the negative headlines, most of them are growing.

All five drugs treat blood cancers — leukemia, lymphoma, and multiple myeloma. All five work by targeting a specific protein on the surface of cancer cells, the way a key fits a specific lock. Yescarta and the others target CD19, a marker found on a type of blood cancer cell. Carvykti targets BCMA, which sits on a different blood cancer cell type called a plasma cell.

The reason Carvykti is growing at 93% year over year while Kymriah is declining is instructive: Carvykti's target biology is cleaner, its manufacturer expanded eligibility to earlier-stage patients in 2024 (meaning more patients qualify), and J&J's commercial infrastructure is more capable than Novartis's in this specific market. The science, the business, and the execution all contributed. That combination — not luck alone — is what separates the growers from the decliners.

Taken together, these five drugs generated over $14 billion in global cell and gene therapy revenue in 2024. The CAR-T market specifically crossed $5 billion in 2025. These are not numbers from a dead industry. They are numbers from an industry in its early commercial phase, with penetration rates still in the low single digits across all the blood cancer markets it addresses.

Why Everyone Is Suddenly Spending Billions on the Next Generation

Here is the clearest signal in this entire market: in a single seven-month stretch from June to December 2025, five of the largest pharmaceutical companies in the world spent a combined $10 billion-plus acquiring cell therapy companies — most of them at a stage before a single commercial patient had been treated.

When companies pay a billion dollars or more for technology that has not yet treated a commercial patient, they are not making a financial bet based on current revenue. They are making a scientific bet based on what they believe the technology will be capable of within five to ten years.

The pattern in the table above is impossible to miss. Five of the six major deals bet on the same thing: the ability to deliver cell therapy directly inside the patient's body, eliminating the complicated and expensive process of extracting cells, engineering them in a laboratory, and returning them. That approach — called in vivo therapy, meaning 'within the living body' — is where pharmaceutical leadership has collectively decided the next $30-50 billion in value will be created.

Gilead's decision is particularly telling. The company that already owns Yescarta — the revenue leader in existing cell therapy — simultaneously cancelled a $2.3 billion deal with a competing technology and redirected that capital into in-body delivery. That is not hedging. That is a directional conviction bet from the company with the most to lose if it gets the call wrong.

Three Frontiers Where the Next Wave Is Building

1. Delivering therapy inside the body

The fundamental problem with current cell therapy is that it is hand-crafted for each patient. Your cells are removed, sent to a facility, engineered over several weeks, quality-tested, and shipped back — all before treatment can begin. The process costs hundreds of millions to build and operate, takes weeks that some patients do not have, and fails in a meaningful percentage of cases because a patient's cells are simply not healthy enough to engineer.

In-body delivery removes all of that. Instead of a manufacturing facility, you need a drug — a carefully designed particle or modified virus that carries genetic instructions, finds the right cells inside the patient's body, and reprograms them in place. If it works reliably, the cost of cell therapy could eventually drop from hundreds of thousands of dollars toward the cost of a conventional biologic drug. The manufacturing constraint disappears. Global access becomes at least theoretically possible.

The biology is promising but genuinely hard. The delivery vehicle has to find the right cells without accidentally reprogramming the wrong ones. Early clinical results from companies like Capstan and EsoBiotec have been encouraging enough that pharma has already spent $10 billion acquiring the platforms — but none of these have yet completed the large clinical trials required for regulatory approval. The next two to three years of trial data will determine whether the billions spent were well placed.

2. Treating autoimmune diseases

This is the surprise story of the past two years, and arguably the more important one commercially.

Autoimmune diseases — lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, and others — are conditions where the immune system mistakenly attacks the patient's own body. The immune cells causing the damage are, in many cases, the same B-cells that cell therapy was designed to eliminate in blood cancer.

Researchers discovered that giving cell therapy to autoimmune patients produces something remarkable: it wipes out the malfunctioning immune cells entirely, and the immune system essentially reboots from scratch. Some patients with severe, treatment-resistant lupus have entered what appears to be drug-free remission — meaning they stopped all medication and their disease remained controlled — after a single cell therapy treatment.

The global autoimmune disease drug market exceeds $150 billion annually. That is more than twice the size of the entire oncology drug market. If cell therapy can reliably produce durable remissions in even a fraction of those patients — at a cost that is eventually manageable — the commercial opportunity is larger than everything the field has attempted to date in cancer.

This is early-stage. No cell therapy is yet approved for autoimmune disease. But the clinical signals are strong enough that three of the six major acquisitions in 2025 were specifically motivated by autoimmune potential, not cancer. The scientific logic is sound. The commercial math is compelling. The clinical validation is the remaining question.

3. Solid tumors — the moonshot

Every cancer that is not a blood cancer is called a solid tumor: lung, breast, colon, pancreatic, liver, and hundreds of others. These account for roughly 90% of all cancer deaths globally. Cell therapy has not cracked any of them.

The reason is biological. Blood cancer cells circulate in the bloodstream, making them accessible to engineered immune cells. Solid tumor cells sit inside tissue, surrounded by a complex local environment that actively suppresses and kills the engineered cells before they can do their job. Finding a clean target — a protein that appears on the tumor but not on critical healthy tissue — is far harder when you are dealing with the breast or the lung than when you are dealing with the blood.

Smaller, earlier bets are being placed here through different cell engineering approaches and combination strategies. No commercial success exists yet. But the potential market — successfully treating the cancers that kill the most people — is so large that even a partial solution would represent one of the most valuable medical breakthroughs in history. This is a 10-to-15-year horizon, not a 3-to-5-year one. But it is where the field is ultimately pointed.

What the Investment Picture Actually Says

Pulling back from the individual bets, the collective message from sophisticated investors and pharmaceutical companies is consistent and worth stating plainly:

The field is not dying.

The first generation had the wrong architecture. The second generation is being built with $10+ billion in committed capital, better biological targets, and the lessons of the first wave's failures built in.

The access problem is still unsolved.

Current therapies remain largely inaccessible to patients outside of major academic medical centers in wealthy countries. In-body delivery, if it works, is the most credible path to changing that. The commercial opportunity and the social good are pointed in the same direction.

China is a serious participant, not just a manufacturer.

Legend Biotech developed the science behind Carvykti — the fastest-growing cell therapy drug. Pregene attracted $1.64 billion from Gilead. Gracell's manufacturing platform was acquired by AstraZeneca for $1.2 billion. Western investors who ignore Chinese biotech innovation in this field are working with incomplete information.

The next value creation opportunity: watching the data

For the specific in vivo CAR-T platform category that drove the 2025 acquisition frenzy, the window of obvious Western acquisition targets is largely closed. The broader CGT opportunity remains wide open — particularly in China, autoimmune applications, and next-generation delivery technologies still emerging from academic labs. The next value creation event will come from clinical trial results — Phase 1 and Phase 2 data from the assets inside companies like Capstan, EsoBiotec, and Orbital over 2026 and 2027. Those readouts are when the real valuation moves will happen.

The Science-First Takeaway

The reason most investors get this story wrong is that they are reading the financial news, not the biology. The financial news shows pricing failures, withdrawn drugs, and companies splitting in two. Those are real events. But the underlying science — engineering immune cells to target specific proteins with precision — has been validated beyond serious doubt by 34,000 treated patients and billions in real commercial revenue.

What has not been validated yet is whether the next generation of delivery mechanisms will work in humans at scale, whether the autoimmune results will hold in larger trials, and whether the economics can eventually reach a global patient population. Those are the open scientific questions — and they are the questions that will determine where the next $50-100 billion of value in this field is created.

An investor who understands the biology can form a view on those questions that a financial analyst cannot. That is the edge that a science-first approach to this market is designed to deliver.

Cell and gene therapy is not dead. It is being rebuilt from the ground up, with better tools, more capital, and a clearer understanding of what went wrong the first time. The pessimists are reading the obituary for Generation 1. Generation 2 has not yet introduced itself.

Disclosure

This article is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or a solicitation to buy or sell any security. RichStorm LLC does not hold positions in any securities mentioned. Readers should conduct their own research and consult a qualified financial professional before making investment decisions. All market data and figures cited reflect publicly available information as of June 2026.